MedTrace Logo

Treating Corneal Thinning Conditions With CCL Vario Riboflavin (CXL)

NCT04731727 · Status: NOT_YET_RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 600

Last updated 2021-05-25

No results posted yet for this study

Summary

Study is testing the efficacy of treating corneal thinning conditions with Vitamin B2 (Riboflavin) and the application on UV Light.

Conditions

  • Keratoconus, Unstable

Interventions

DRUG

Riboflavin

Corneal cross linking achieved by combination of Riboflavin and ultraviolet light

Sponsors & Collaborators

  • Kent Wellish MD

    lead OTHER

Principal Investigators

  • Kent L Wellish, MD · Wellish Vision Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-30
Primary Completion
2026-12-31
Completion
2026-12-31
FDA Drug
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04731727 on ClinicalTrials.gov